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Background: Gastric cancer is the third leading cause of cancer-related mortality in China, and the long-term survival
for locally advanced gastric cancer is very poor. Simple surgery cannot yield an ideal result because of the high
recurrence rate after tumor resection. Preoperative chemotherapy could help to reduce tumor volume, improve the
R0 resection rate (no residual tumor after surgery), and decrease the risk of local tumor recurrence. The aim of this
study was to evaluate the influence of pathological differentiation in the effect of preoperative chemotherapy for
patients with locally advanced gastric cancer.
Methods: Patients with locally advanced gastric cancer (n = 32) received preoperative chemotherapy under the
XELOX (capecitabine plus oxaliplatin) regimen. According to pathological examination, patients’ tumors were classified
into better (well and moderate) and poorly differentiated (lower differentiated and undifferentiated) groups, and the
clinical response rate, type of gastrectomy, and negative tumor residual rate were compared between the two groups
of patients. Morphological changes and toxic reactions were monitored after chemotherapy.
Results: The results showed that the clinical response rate in the better differentiated group was significantly higher
than that in the poorly differentiated group (100% versus 25%, P = 0.000). The partial gastrectomy rate in the better
differentiated group was significantly higher than that in the poorly differentiated group (87.5% versus 25% P = 0.000).
A significant shrinking of tumor and necrosis of tumor tissues caused by chemotherapy could be observed.
Conclusions: In conclusion, the better differentiated group with locally advanced gastric cancer is suitable for
preoperative chemotherapy under the XELOX regimen, and as a result of effective preoperative chemotherapy,
much more gastric tissue can be preserved for the better differentiated group.
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Gastric cancer is one of the most common malignancies
in Asia, especially in China, Korea, and Japan [1]. It is
the third leading cause of cancer-related mortality in
China, and Chinese patients with gastric cancer account
for 42% of the worldwide patient population with gastric
cancer [2]. Surgical resection of the tumor is the most
effective approach in increasing the long-term sur-
vival of patients with early stage gastric cancer [3].* Correspondence: sunlibo0431@sina.com
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unless otherwise stated.The five-year survival rate of patients with resectable
gastric cancer in advanced stages (stages III or IV) can be
improved through combined surgical management with
perioperative chemotherapy [4]. The benefits of pre-
operative chemotherapy (neo-adjuvant chemotherapy)
for patients with gastric cancer are as follows: reduces
tumor volume, which results in tumor downstage, im-
proves the R0 resection rate (no residual tumor after
surgery), acts on micrometastasis, decreases the risk of
local tumor recurrence, and aids in evaluating tumor
chemosensitivity to cytotoxic drugs [5-10]. In locally ad-
vanced gastric cancer, the primary tumor is invaded. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Sun et al. World Journal of Surgical Oncology 2014, 12:280 Page 2 of 5
http://www.wjso.com/content/12/1/280through the submucosal layers of gastric tissues, with
regional nodal involvement, and occupies most of the
normal gastric cell lines [11,12]. Although the long-
term effects remain controversial, preoperative chemo-
therapy for locally advanced gastric cancer has shown
encouraging rates of pathologic complete response and
R0 resection, with acceptable rates of acute and late
toxicities [13,14]. However, no report was found on
the factor of pathological differentiation in preopera-
tive chemotherapy of locally advanced gastric cancer.
Therefore, the aim of this study was to evaluate the
influence of pathological differentiation in the effect of
preoperative chemotherapy for patients with locally
advanced gastric cancer.
In this study, we compared the clinical response rate
of preoperative chemotherapy between better and poorly
differentiated locally advanced gastric cancer, and dis-




Patients who had received preoperative chemotherapy
and surgical treatment for locally advanced gastric
cancer in the gastrointestinal department of the China-
Japan Union Hospital of Jilin University, China, be-
tween April 2009 and March 2013, were retrospectively
reviewed. The preoperative diagnosis was made through
endoscopy, biopsy, endoscopic ultrasound, and en-
hanced computed tomography. The cancer staging was
evaluated according to the Union for International
Cancer Control tumor-node-metastasis classification
(sixth edition) [15]. Patients were fully informed about
the side effects of preoperative chemotherapy and sur-
gery, and they chose this treatment by themselves
voluntarily. Preoperative chemotherapy for locally ad-
vanced gastric cancer was approved by the Medical
Ethics Committee of the China-Japan Union Hospital
of Jilin University, China.
Preoperative chemotherapy and surgery
As preoperative chemotherapy, the XELOX (capecitabine
plus oxaliplatin) regimen was used in this study [14], as
follows: intravenous infusion of oxaliplatin 130 mg/m2
over 2 hours on Day 1, followed by capecitabine 1,000
mg/m2 orally twice daily for 2 weeks. This cycle was re-
peated once every 3 weeks, and the patients were given
two cycles before evaluation of the chemotherapeutic ef-
fect. Clinical efficacy was evaluated by computed tomog-
raphy and endoscopy. Patients with resectable tumors
after chemotherapy were chosen for surgery. Patients
with unresectable tumors after two cycles of chemother-
apy continued to receive chemotherapy (for a total of
four cycles), after which the efficacy was again evaluatedby computed tomography and endoscopy. At this point,
patients with resectable tumors would undergo surgery,
and patients with unresectable tumors would be ex-
cluded from the study. Some patients whose tumors
were resectable initially, but for whom total gastrec-
tomy seemed unavoidable were also included in this
study. The choice of surgical type depended on the
treating surgeon’s preference, primary tumor location,
and extent of disease.
Evaluation for efficacy and adverse events monitoring
The tumors’ reaction to prechemotherapy was evaluated
as follows: (1) complete response, complete disappear-
ance of the tumor; (2) partial response, a decrease of
more than 30% in tumor size; (3) progressive disease,
tumor size increased, more than 20%; and (4) stable dis-
ease, no change found in tumor size. The clinical response
rate was calculated as follows:
Complete response þ Partial responseð Þ
=Measurable number of cases  100%
Repeated computed tomography was used to evaluate
the change in size of the metastasizing lymph node, and
repeated endoscopy examination was used to evaluate
changes in the primary gastric carcinoma. Patients’ liver
and kidney function, bone marrow hematopoiesis, gastro-
intestinal reactions, and related adverse events were closely
monitored during the treatment. Toxic reactions were
evaluated using the National Cancer Institute Common
Toxicity Criteria (version 3.0) [14].
Statistical analysis
The patient’s age and body mass index were presented
as χ ± standard deviation. The chi-square test was used
to compare the differences in clinical response rate, op-
eration type, and R0 resection rate. All statistical ana-
lyses were performed using SPSS software, version 11.0
(SPSS Inc, Chicago, United States).
Results
Patients’ characteristics
A total of 32 patients with locally advanced gastric cancer
were enrolled in this study. The patients’ characteristics
(age, sex, and body mass index (kg/m2)), pathological de-
gree of differentiation, and preoperative pathological stages
are listed in the Table 1.
Response rate of preoperative chemotherapy
Of the 32 patients, no patient was rated as having
complete response or progressive disease, 20 patients
were rated as having a partial response, and 12 patients
were rated as having stable disease. The overall clinical
response rate was 62.5%. Altogether, 26 patients (81.3%)
Table 1 Patients’ general characteristics
Better
differentiated
group (n = 16)
Poorly
differentiated
group (n = 16)
P
Male:female 9:7 11:5 0.465
Average age (years) 53.80 ± 4.21 52.50 ± 4.67 0.522







III 12 13 0.669
IV 4 3 0.059
Mean number of
chemotherapy cycles
2.8 ± 0.75 3.4 ± 0.50
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mors with poor differentiation were considered as unre-
sectable after four cycles of preoperative chemotherapy.
Morphological changes after preoperative chemotherapy
Figures 1A and 1B show a significant change in tumor
size (partial response) before and after preoperative
chemotherapy. Figures 1C and 1D show the necrosis of
tumor tissue surrounded by inflammatory tissue after
preoperative chemotherapy.Figure 1 Morphological changes of local advanced gastric cancer bef
carcinoma (endoscopy view) before chemotherapy. (B) Obviously shrunk g
patient. (C) Tumor tissue surrounded by inflammatory tissue (arrow) after c
cancer cells showed obvious nucleus necrosis after chemotherapy. H & E stComparison of response and surgical results between
different pathological differentiations
The pathological differentiation was classified into two
groups: better differentiated (well and moderately differ-
entiated) and poorly differentiated (lower differentiated
and undifferentiated). No difference was found in the
age, sex, body mass index, tumor-node-metastasis stage,
and tumor size between the two groups. The clinical
response rate in the better differentiated group was sig-
nificantly higher than that in the poorly differentiated
group. The partial gastrectomy rate in the better differ-
entiated group was significantly higher than that in the
poorly differentiated group (Table 2). Neither death nor
severe complication occurred in this study. No differ-
ence was found in surgical time and incidence rate of
postoperative complications between the well and poorly
differentiated groups.
Toxicity
No treatment termination or death occurred as a result
of a toxic reaction. During preoperative chemotherapy,
there were different degrees of toxic and adverse reac-
tions, mainly myelosuppression, liver dysfunction, and
gastrointestinal reactions. Toxic reaction occurred in all
the patients receiving preoperative chemotherapy, to dif-
ferent extents. Leukopenia (n = 24; 75%) was the most
commonly reported adverse reaction. As markers of liver
injury, alanine aminotransferase and aspartate amino-
transferase levels were increased in nine (28.1%) and
eight patients (25%), respectively. Nausea and vomitingore and after preoperative chemotherapy. (A) Gross gastric
astric carcinoma (endoscopy view) after chemotherapy in the same
hemotherapy. H & E staining, original magnification ×40. (D) Gastric
aining, original magnification ×100.
Table 2 Comparison of chemotherapy results between
better and poorly differentiated groups
Better
differentiated
group (n = 16)
Poorly
differentiated
group (n = 16)
P
Clinical reaction rate 100% (16/16) 25% (4/16) 0.000
Partial gastrectomy 87.5% (14/16) 25% (4/16) 0.000
Total gastrectomy 12.5% (2/16) 37.5% (6/16) 0.654
Unresectable cases
Prechemotherapy 18.7% (3/16) 62.5% (10/16) 0.012
Postchemotherapy 0 (0/16) 37.5% (6/16) 0.024
R0 resection rate 100% (16/16) 62.5% (10/16) 0.018
Toxicity reaction rate 100% (16/16) 100% (16/16)
R0, no residual tumor after surgery.
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patients (59.3%) reporting vomiting, and 25 patients
(67.7%) reporting nausea. Toxic neurological reaction oc-
curred in 21 patients (78.1%). The toxic reactions reported
in this study were similar with previous reports [14,16].
Discussion
Unlike early gastric cancer, surgical treatment of ad-
vanced gastric cancer is not satisfactory because of
tumor local invasion and severe lymph node metastasis,
with a survival time of no longer than one year [17,18].
However, surgery is still the primary treatment modality
for achieving a potential cure and can be beneficial in
the palliation of advanced gastric cancer [19,20]. The
high recurrence rate after surgical resection for locally
advanced gastric cancer was considered the main reason
for poor treatment results [21,22]. Many clinical studies
have shown that chemotherapy can downstage the
tumor, eliminate micrometastasis, and make some unre-
sectable gastric cancers resectable, thereby prolonging
the survival time of patients [23-26].
Recently, the XELOX regimen has been used as a new
chemotherapeutic strategy for locally advanced gastric
cancer patients, which was easier to accept in clinical
practice, with an encouraging 63% clinical response rate
and a median survival time of 11.9 months [27]. In the
present study, similar results were obtained, with a clin-
ical response rate of 62.5% and 81.3% R0 resection. On
comparing the clinical response rate between the better
differentiated and poorly differentiated groups, it was
found that the better differentiated group showed a
100% clinical response rate, whereas the poorly differen-
tiated group showed only 25%. This result strongly sug-
gested that well and moderately differentiated locally
advanced gastric cancer is a candidate for preopera-
tive chemotherapy. Moreover, total gastrectomy could
be avoided in patients with well differentiated gastriccancer, since the recovery of normal gastric tissue was a
result of effective preoperative chemotherapy. Although
the short-term results for better differentiated locally
advanced gastric cancer were promising in this study,
longer survival times need to be observed further.
After chemotherapy, well differentiated larger tumors
were found to be obviously shrunken. After H & E stain-
ing, the necrosis of tumor tissues was easily seen under
a microscope, commonly surrounded by inflammatory
tissue, forming a typical tissue morphology after sensi-
tive chemotherapy. Based on the effective chemotherapy,
the recovery of normal gastric tissues resulted in the
possibility of preserving some stomach, other than re-
moving the total stomach, to obtain R0 resection.
The toxic reactions to chemotherapy were very common
and were the main cause of patients refusing or discontinu-
ing chemotherapy. In the present study, patients experi-
enced different degrees of toxic and adverse reactions,
especially during the first cycle. The patients could recover
from leukopenia and liver function abnormality after two
to three weeks of rest. Nausea and vomiting often occurred
during the intravenous infusion of oxaliplatin at the begin-
ning of therapy, wherein liquid transfusion was necessary
to keep the acid-base balance and to supply nutritional en-
ergy. For patients with severe toxic reactions, delaying the
treatment was deemed necessary.
There are several limitations of this study to note.
Firstly, this study was a retrospective study. Retrospect-
ive studies are inherently less robust than prospective
studies. Secondly, the sample sizes of the groups were
relatively small. It is possible that additional differences
would emerge in a larger study. Hence, a large prospect-
ive study at multiple centers could provide more robust
and generalizable information about the influence of
pathological differentiation in the effect of preoperative
chemotherapy for patients with locally advanced gastric
cancer.
Conclusions
From this study, it is concluded that better differentiated
locally advanced gastric cancer is suitable for preopera-
tive chemotherapy under the XELOX regimen. As a re-
sult of effective preoperative chemotherapy, much more
gastric tissue can be preserved in patients with better
differentiated locally advanced gastric cancer.
Abbreviation
H & E: hematoxylin and eosin, R0 resection, no residual tumor after surgery.
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